Introduction: Prostate cancer is the most commonly diagnosed malignant neoplasm and one of the leading causes of death among the male population in Brazil. Given the disease’s prevalence, this study proposes an analysis of the geographic distribution of incidence and mortality throughout the national territory, focusing on identifying regional variations and areas of greater vulnerability. Objectives: Collect data on deaths and hospitalizations due to prostate cancer, as well as general data on deaths and hospitalizations, by region of Brazil, from 2013 to 2023, analyzing them for regional disparities in the occurrence of the disease, hospitalization rates, and access to treatment. Methods: This is a cross-sectional, retrospective, and quantitative study. Data were obtained from the Mortality Information System (SIM) and the Hospital Information System (SIH), accessed via TabNet, from the Department of Informatics of the Unified Health System (DATASUS). The collected data include the number of hospitalizations—used as a proxy variable for estimating incidence—and the number of deaths—used to calculate mortality—due to malignant neoplasm of the prostate, covering the all five geographic regions of Brazil from January 2013 to December 2023. The data were then analyzed by comparing these figures with the overall rates of deaths and hospitalizations recorded in the same period. Results: The main findings include: In the North Region, 9,643 deaths from prostate cancer were recorded, accounting for 1.6% of the total 596,388 deaths in the region, along with 9,680 hospital admissions related to the disease, representing 0.2% of the total 4,114,850 admissions. In the Northeast, there were 47,295 deaths (2% of 2,275,342) and 84,251 hospitalizations (0.6% of 13,442,671). The Central-West Region recorded 12,271 deaths (2% of 609,655) and 20,331 hospitalizations (0.4% of 4,255,575). In the Southeast Region, 71,865 deaths were reported (1.8% of 3,792,116) and 177,259 hospitalizations (0.8% of 21,651,238). Finally, the South Region reported 29,048 deaths (2.2% of 1,304,289) and 53,617 hospitalizations (0.5% of 9,927,470) Conclusion: It was concluded that the percentages of deaths due to prostate cancer were higher in the South, Central-West, and Northeast regions, while hospitalizations were more frequent in the Southeast and Northeast regions, which may indicate better access to treatment in these latter areas. In the North region, there is a close similarity between the number of deaths and hospitalizations due to malignant neoplasm of the prostate. This pattern is also observed in the South region, which presents the highest proportion of deaths from the disease but a low percentage of hospitalizations. These data may indicate failures in early diagnosis and inadequate medical infrastructure, hindering favorable outcomes in cases of malignant prostate neoplasms. Therefore, the implementation of public health policies focusing on prevention and treatment is recommended.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
